Status:
ACTIVE_NOT_RECRUITING
Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Prostate Cancer
Eligibility:
MALE
20+ years
Phase:
NA
Brief Summary
Prostate cancers (PCA) are a heterogeneous group which include indolent tumors that has no clinical significance to very aggressive cancer that could result in morbidities and mortality. Thus, an accu...
Detailed Description
Prostate cancer is the 2nd most common malignancy in the world as well as the leading cancer in male population in Taiwan. The treatment selections of prostate cancer are limited by the uncertainty of...
Eligibility Criteria
Inclusion
- Aged over 20 years old.
- Suspected or confirmed prostate cancer.
- Undergoing prostate mpMRI before clinical treatment.
- Normal renal function(i.e.: estimated GFR ≧60).
- No allergy history to gadolinium based contrast agent.
- Agree to participate this study and sign informed consent.
Exclusion
- mpMRI photography not completed.
- mpMRI images are damaged or poor in quality and cannot be interpreted.
- Without pathological examination confirmed prostate cancer.
- Patient withdraw informed consent.
Key Trial Info
Start Date :
February 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT06126172
Start Date
February 15 2022
End Date
December 31 2025
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Li-Jen Wang
Taoyuan District, Taiwan, 333